Tumor-immune hybrid cells are distinguished from cancer-associated macrophage-like cells (CAMLs) and immune cells that have phagocytosed dying cancer cells because they have cell surface antigen expression of both cancer and immune cell epitopes5. This evidence concerns the gene CD53 and cancer.